GDC-0623, also known as G-868, is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
MEK Inhibitor Related Products:
Selumetinib; Mirdametinib (PD0325901); Trametinib; PD184352 (CI-1040); PD98059; BIX02189; U0126-EtOH; Pimasertib; BIX02188; TAK-733; Binimetinib (MEK162); SL327; Refametinib; GDC-0623; RO5126766 (CH5126766); Cobimetinib; APS-2-79 hydrochloride; AZD8330